CD19 and leukemia: Antibodies featuring engineered Fc domains or bispecific antibodies are now considered part of our current armamentarium for leukemia expressing CD19 or CD20 (1–3); as are T cells engineered to express chimeric antigen receptors (CARs) that target CD19 (4, 5).